The pilot line focuses on innovative medical devices, such as wearable sensors for monitoring cardiovascular diseases and microfluidic sensors for early cancer detection. By providing a regulated environment for prototype production, the facility helps overcome common barriers that startups face when transitioning from research to market-ready products. It also supports certification processes, reducing time and cost in bringing new technologies to patients.
Key areas of focus include preventive monitoring of cardiovascular diseases, metabolic syndromes, and early cancer detection, with devices designed to be comfortable and discreet. Additionally, the pilot line enables quick diagnostics, allowing healthcare providers to perform on-site tests, ultimately giving patients the possibility to reach adequate care more quickly.
VTT aims to collaborate with medical device companies, universities, and healthcare organizations to bring innovations to the market faster. The pilot line began operations in early 2025 and is part of VTT’s broader efforts in advancing medical device technologies in Europe, including leading the EU ChipsAct programme.
Contact person: Jussi Hiltunen, Research Professor
jussi.hiltunen@vtt.fi
+358407795831
Source (text and image): VTT
